Fetzima Withdrawal & Tapering Guide
levomilnacipran
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
In short
Fetzima (levomilnacipran) is an SNRI with a half-life of 12 hours. Active enantiomer of milnacipran with stronger norepinephrine reuptake inhibition.
- Class
- SNRI
- Half-life
- 12 hours
- Common doses
- 20mg, 40mg, 80mg, 120mg
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Levomilnacipran is the more pharmacologically active enantiomer of milnacipran. It is an SNRI approved for major depressive disorder with approximately 2:1 selectivity for norepinephrine over serotonin reuptake inhibition.
20mg, 40mg, 80mg, 120mg
Extended-release capsules: 20mg, 40mg, 80mg, 120mg
Category C (risk cannot be ruled out)
Mechanism of Action
Potent dual reuptake inhibitor of serotonin and norepinephrine with preferential norepinephrine activity (NET > SERT, approximately 2:1 ratio). The active S-enantiomer of milnacipran.
Taper Notes
Active enantiomer of milnacipran with stronger norepinephrine reuptake inhibition. Extended-release formulation allows once-daily dosing. Taper gradually over weeks.
Hyperbolic Tapering Guidance
Reduce dose gradually. Consider stepping down by one dose level (e.g., 120→80→40→20) every 1–2 weeks. Extended-release capsules should not be crushed or opened.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (risk of serotonin syndrome)
- Strong CYP3A4 inhibitors (ketoconazole) — max dose 80mg/day
- Serotonergic drugs increase serotonin syndrome risk
Food Interactions
- No significant food effect on absorption
- May be taken with or without food
Contraindications
- MAOIs within 14 days
- Uncontrolled narrow-angle glaucoma
- Known hypersensitivity to levomilnacipran or milnacipran
Toxicity
Serotonin syndrome risk. Blood pressure and heart rate increases. Urinary hesitation.
Pharmacokinetics
ADME Profile
Well absorbed, bioavailability ~92%. Tmax ~6–8 hours (extended-release). Food does not affect AUC.
387–473 L
Hepatic via CYP3A4 (major) with minor contribution from CYP2C8, CYP2C19, CYP2D6, and CYP2J2. Desethyl metabolite (inactive).
Renal (58% unchanged).
22%
~21 L/hr
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
The arithmetic of a proportional reduction
The Maudsley Deprescribing Guidelines and NICE NG222 describe reducing SNRI medications by a proportion of the previous dose rather than by a fixed amount, so each cut is smaller than the last. The table shows what that arithmetic produces at 10% per step, using 40 mg only as a worked example. How large each step is, how long it is held, and whether this pattern applies at all are decisions for the person and their prescriber.
| Step | % of starting dose | Worked example (40 mg start) |
|---|---|---|
| Start | 100% | 40 mg |
| Step 1 | 90% | 36 mg |
| Step 2 | 81% | 32.4 mg |
| Step 3 | 73% | 29.2 mg |
| Step 4 | 66% | 26.2 mg |
| Step 5 | 59% | 23.6 mg |
| Step 6 | 53% | 21.3 mg |
| Step 7 | 48% | 19.1 mg |
| Step 8 | 43% | 17.2 mg |
This is an illustration of a published method, not a schedule for anyone. It does not account for how long you have taken Fetzima, your current dose, formulation, or history. TaperCommunity does not recommend doses or dose changes; those are agreed with your prescriber.
Frequently asked questions about Fetzima
What are the withdrawal symptoms of Fetzima (levomilnacipran)?
Common withdrawal symptoms of Fetzima (levomilnacipran) include: dizziness, nausea, headache, irritability, insomnia, fatigue, hyperhidrosis. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Fetzima (levomilnacipran)?
Active enantiomer of milnacipran with stronger norepinephrine reuptake inhibition. Extended-release formulation allows once-daily dosing. Taper gradually over weeks. Reduce dose gradually. Consider stepping down by one dose level (e.g., 120→80→40→20) every 1–2 weeks. Extended-release capsules should not be crushed or opened.
Can I stop Fetzima cold turkey?
Stopping Fetzima abruptly is not recommended. Its half-life is 12 hours, and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Fetzima stay in your system?
Fetzima (levomilnacipran) has a half-life of 12 hours. A drug is mostly cleared after about five half-lives, so Fetzima is largely out of the body about 3 days after the last dose, longer in older adults or with liver or kidney impairment. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Sources & References
Fetzima (levomilnacipran) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
- Framer A 2021 — The patient voice: an exploration of the experience of withdrawal from antidepressants (Therapeutic Advances in Psychopharmacology)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.